)
Amphastar Pharmaceuticals (AMPH) investor relations material
Amphastar Pharmaceuticals 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategic direction, business model, and integration
Operates a fully integrated model with in-house R&D, manufacturing, and marketing, supporting both internal development and strategic acquisitions.
Maintains full control over quality and compliance across all stages, with vertically integrated operations for flexibility and scalability.
Dual growth strategy: internal product development and targeted acquisitions, such as Baqsimi and facilities in the US and France.
Expanded international footprint to over 26 countries, leveraging acquisitions to support proprietary launches.
Focuses on high-quality, high-efficiency, and high-technology products for competitive advantage.
Growth strategy, financial performance, and market strategy
Revenue grew from $295M in 2018 to $732M in 2024, with adjusted net income margin rising to 27.4%.
Annual EPS increased from $0.64 in 2020 to $4.5 in 2024, with a 20% CAGR in revenue and 57% CAGR in adjusted EPS.
R&D investment reached $351M over five years, with annual R&D expenses rising and expected to increase further.
2026 revenue growth forecast revised to mid-single digit to low double digits, driven by new launches and expanded sales.
Strategic withdrawal from unprofitable international Baqsimi markets to improve margins.
Pipeline evolution, R&D highlights, and innovation
By 2026, proprietary and biosimilar products are projected to comprise 85% of the pipeline, up from 37% in 2021.
Proprietary pipeline includes intranasal epinephrine, reformulated Primatene Mist, and several in-licensed NCEs.
Promising peptide and biologics pipeline targets oncology, ophthalmology, endocrinology, and rheumatology.
AMP-109 demonstrated >99% tumor inhibition in preclinical pancreatic cancer models; AMP-110 is a fully synthetic corticotropin analog with reduced impurity and viral risk.
Proprietary delivery technologies include intranasal and metered dose inhaler platforms, supporting innovation in drug administration.
- TimeTickerHeadlineOpen
- 6 FebHTOO
Resale registration for 71,429 shares via warrant, with proceeds only on exercise; financial risks persist. - 6 FebVSAT
Q3 revenue up 3% to $1.16B, net income $25M, strong cash flow, Ligado boost, satellite focus. - 6 FebWEC
Targets 7–8% EPS growth, $37.5B capex, and coal exit by 2032 amid surging data center demand. - 6 FebBR
Q2 FY26 recurring revenue grew 8% and adjusted EPS guidance was raised to 9-12%. - 6 FebFFWM
Merger vote includes new non-voting stock class with limited conversion and no voting rights. - 6 FebKKR
Charter amendments seek to modernize governance and establish one share, one vote by 2026. - 6 FebARI
Proposed $9B real estate loan portfolio acquisition highlights disciplined, long-term strategy. - 6 FebSMCI
Q2 revenue jumped 123% to $12.7B, with FY26 guidance raised to at least $40B. - 6 FebRJF
Record revenues and assets, higher dividend, and acquisitions despite lower net income. - 6 FebFFIE
Raising capital for global EV and AI expansion, with regulatory and dilution risks highlighted.
Next Amphastar Pharmaceuticals earnings date
Next Amphastar Pharmaceuticals earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)